Rosiglitazone and cardiovascular risk
- First Online:
- 58 Downloads
A meta-analysis of 42 clinical trials suggested that rosiglitazone, a widely used thiazolidinedione, was associated with a 43% greater risk of myocardial infarction (P = 0.03) and a 64% greater risk of cardiovascular death (P = 0.06). However, a number of criticisms have been raised that potentially undermine the conclusions of this analysis. In this article, we point out some of these limitations, summarize the currently available evidence concerning rosiglitazone and cardiovascular risk, share implications for drug safety evaluation, and offer practical recommendations to health care providers. We conclude that the data showing the increased risk for myocardial infarction and death from cardiovascular disease for diabetic patients taking rosiglitazone are inconclusive.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Rosiglitazone: seeking a balanced perspective [editorial]. Lancet 2007, 369:1834.Google Scholar
- 5.Strom BL: Statements for the hearing record. Committee on Oversight and Government Reform. United States House of Representatives, June 7, 2007. Available at: http://republicans.oversight.house.gov/Media/PDFs/20070607StromTS.pdf. Accessed on May 17, 2008.
- 10.FDA Briefing Document: Advisory Committee meeting July 30th 2007 to discuss cardiovascular ischemic events with Avandia. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-FDA-backgrounder.pdf. Accessed on May 17, 2008.
- 11.Advisory Committee Briefing Document: Cardiovascular safety of rosiglitazone. Philadelphia: GlaxoSmithKline; 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-01-sponsor-backgrounder.pdf. Accessed on May 17, 2008.
- 14.Richter B, Bandeira-Echtler E, Bergerhoff K, et al.: Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; Issue 3. Art No: CD006063. DOI: 10.1002/14651858.CD006063.pub2.Google Scholar
- 20.Wood S: FDA advisory panels acknowledge signal of risk with rosiglitazone but stop short of recommending its withdrawal. Available at: http://www.theheart.org/article/804403. Accessed on January 20, 2008.
- 21.European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and Pioglitazone. Doc. Ref. EMEA/484277/2007. Available at: http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf. Accessed on May 17, 2008.
- 22.FDA adds boxed warning for heart-related risk to anti-diabetes drug Avandia. Available at http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html. Accessed on May 17, 2008.
- 24.Questions and Answers: Use of Rosiglitazone (Avandia) in the National Heart, Lung, and Blood Institute’s Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) and Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trials. Available at http://www.nhlbi.nih.gov/new/press/07-rosi-qa.htm. Accessed on May 17, 2008.
- 25.Beals JK: VA diabetes trial shows that intensive glucose control has little effect on cardiovascular risk. Available at: http://www.theheart.org/article/875871.do. Accessed on June 18, 2008.
- 26.Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PRO spective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.PubMedCrossRefGoogle Scholar
- 27.Dargie HJ, Hildebrandt PR, Riegger GA, et al.: A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 2007, 49:1696–1804.PubMedCrossRefGoogle Scholar
- 32.Committee on the Assessment of the US Drug Safety System. Baciu A, Stratton K, Burke SP, (eds): The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: National Academies Press; 2006.Google Scholar
- 33.Vicari KA: Cancer Drugs: No Remission for FDA Omission. Wall Street Journal, August 16, 2007.Google Scholar
- 35.Approval letter. Application number 021071. Center for Drug Evaluation and Research. Available at: http://www.fda.gov/cder/foi/nda/99/21071_Avandia_Approv.pdf. Accessed on May 17, 2008.
- 37.Final PDUFA Recommendations Transmitted to Congress Will Strengthen Drug Review and Drug Safety. Available at http://www.fda.gov/bbs/topics/NEWS/2007/NEW01592.html. Accessed on May 17, 2007.